» Articles » PMID: 20086148

Genetic Dissection of Azole Resistance Mechanisms in Candida Albicans and Their Validation in a Mouse Model of Disseminated Infection

Overview
Specialty Pharmacology
Date 2010 Jan 21
PMID 20086148
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Principal mechanisms of resistance to azole antifungals include the upregulation of multidrug transporters and the modification of the target enzyme, a cytochrome P450 (Erg11) involved in the 14alpha-demethylation of ergosterol. These mechanisms are often combined in azole-resistant Candida albicans isolates recovered from patients. However, the precise contributions of individual mechanisms to C. albicans resistance to specific azoles have been difficult to establish because of the technical difficulties in the genetic manipulation of this diploid species. Recent advances have made genetic manipulations easier, and we therefore undertook the genetic dissection of resistance mechanisms in an azole-resistant clinical isolate. This isolate (DSY296) upregulates the multidrug transporter genes CDR1 and CDR2 and has acquired a G464S substitution in both ERG11 alleles. In DSY296, inactivation of TAC1, a transcription factor containing a gain-of-function mutation, followed by sequential replacement of ERG11 mutant alleles with wild-type alleles, restored azole susceptibility to the levels measured for a parent azole-susceptible isolate (DSY294). These sequential genetic manipulations not only demonstrated that these two resistance mechanisms were those responsible for the development of resistance in DSY296 but also indicated that the quantitative level of resistance as measured in vitro by MIC determinations was a function of the number of genetic resistance mechanisms operating in any strain. The engineered strains were also tested for their responses to fluconazole treatment in a novel 3-day model of invasive C. albicans infection of mice. Fifty percent effective doses (ED(50)s) of fluconazole were highest for DSY296 and decreased proportionally with the sequential removal of each resistance mechanism. However, while the fold differences in ED(50) were proportional to the fold differences in MICs, their magnitude was lower than that measured in vitro and depended on the specific resistance mechanism operating.

Citing Articles

Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management.

Akinosoglou K, Livieratos A, Asimos K, Donders F, Donders G Pharmaceutics. 2025; 16(12.

PMID: 39771534 PMC: 11678211. DOI: 10.3390/pharmaceutics16121555.


Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole.

Kukurudz R, Chapel M, Wonitowy Q, Adamu Bukari A, Sidney B, Sierhuis R G3 (Bethesda). 2022; 12(9).

PMID: 35881695 PMC: 9434289. DOI: 10.1093/g3journal/jkac156.


How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems.

Pellaton N, Sanglard D, Lamoth F, Coste A Front Cell Infect Microbiol. 2022; 12:859439.

PMID: 35601096 PMC: 9114767. DOI: 10.3389/fcimb.2022.859439.


Three Related Enzymes in Candida albicans Achieve Arginine- and Agmatine-Dependent Metabolism That Is Essential for Growth and Fungal Virulence.

Schaefer K, Wagener J, Ames R, Christou S, MacCallum D, Bates S mBio. 2020; 11(4).

PMID: 32788384 PMC: 7439472. DOI: 10.1128/mBio.01845-20.


Effect of testosterone and estrogen supplementation on the resistance to systemic infection in mice.

Arroyo-Mendoza M, Peraza K, Olson J, Adler-Moore J, Buckley N Heliyon. 2020; 6(7):e04437.

PMID: 32685740 PMC: 7358272. DOI: 10.1016/j.heliyon.2020.e04437.


References
1.
Odds F, Bougnoux M, Shaw D, Bain J, Davidson A, Diogo D . Molecular phylogenetics of Candida albicans. Eukaryot Cell. 2007; 6(6):1041-52. PMC: 1951527. DOI: 10.1128/EC.00041-07. View

2.
. EUCAST Technical Note on voriconazole. Clin Microbiol Infect. 2008; 14(10):985-7. DOI: 10.1111/j.1469-0691.2008.02087.x. View

3.
Morschhauser J, Barker K, Liu T, BlaB-Warmuth J, Homayouni R, Rogers P . The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 2007; 3(11):e164. PMC: 2048531. DOI: 10.1371/journal.ppat.0030164. View

4.
MacCallum D, Odds F . Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses. 2005; 48(3):151-61. DOI: 10.1111/j.1439-0507.2005.01121.x. View

5.
Sanglard D, Ischer F, Monod M, Bille J . Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (Reading). 1997; 143 ( Pt 2):405-416. DOI: 10.1099/00221287-143-2-405. View